<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916432</url>
  </required_header>
  <id_info>
    <org_study_id>ky20182050-1</org_study_id>
    <nct_id>NCT03916432</nct_id>
  </id_info>
  <brief_title>HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population</brief_title>
  <official_title>HELIOS China Registry: A Prospective, Single-arm, Multicenter Study to Evaluate the HELIOS Biodegradable Polymer Sirolimus-eluting Stent in a 'Real-World' Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Luhe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cangzhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Shantou University Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western Central Hospital of Hainan Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Hainan Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huizhou Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Yulin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Armed Police Corps Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an No.3 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaifeng Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhoupu Hospital, Pudong New Area, Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huangshan Shoukang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Southern Anhui Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Qiqihar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jiamusi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Shenyang Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yingkou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the safety and efficacy of biodegradable polymer sirolimus-eluting
      coronary stent system (HELIOS) in patients with coronary artery disease . The primary
      endpoint is target lesion failure, a composite endpoint of cardiac death, target vessel
      related myocardial infarction and clinically-driven target lesion revascularization at 1 year
      follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single arm clinical registry investigating the safety and
      efficacy of biodegradable polymer sirolimus-eluting coronary stent system(HELIOS) in patients
      with coronary artery disease . The HELIOS (Kimley Medical, Shenzhen, China) completed
      biodegradable polymer sirolimus-eluting stent (SES) is a novel polylactic-co-glycolic acid
      (PLGA),polymer cobalt-chromium DES with titanium oxides (TiO) film as the tie-layer.In total,
      we plan to recruit 3000 patients (HELIOS)in real world setting. The patients will be followed
      clinically at 1-, 6- month and 1-, 3-, 5-year. All clinical data will be collected and
      managed by statistical center, clinical endpoint adjudication committee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target lesion failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>a composite endpoint of cardiac death, target lesion related myocardial infarction, and/or target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient oriented composite endpoint</measure>
    <time_frame>1、6、12、36、60 months</time_frame>
    <description>a composite endpoint of all cause death, all myocardial infarction and all revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>1、6、12、36、60 months</time_frame>
    <description>including cardiac and non-cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>1、6、12、36、60 months</time_frame>
    <description>death from cardiac cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1、6、12、36、60 months</time_frame>
    <description>All myocardial infarction (MI) data were reported based on extended historical definitions.MI was always considered a target vessel, unless there was documented proof that the infarction arose from the nontreated coronary artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1、6、12、36、60 months</time_frame>
    <description>Stent thrombosis (ST) was defined according to Academic Research Consortium criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>1、6、12、36、60 months</time_frame>
    <description>TLR was defined as any repeat revascularization by PCI or CABG</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HELIOS biodegradable polymer sirolimus-eluting stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HELIOS biodegradable polymer sirolimus-eluting stents</intervention_name>
    <description>HELIOS biodegradable polymer sirolimus-eluting stents</description>
    <arm_group_label>Interventional group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1）18-85 years old, male or non-pregnancy female; 2）Patients with coronary artery disease
        who match the indication of stent implantation; 3）Patients who can understand the nature of
        the study, agree to participate and accept clinical follow-up

        Exclusion Criteria:

          1. Patients who can not tolerate the material or medication in this study; Pregnancy or
             lactation women

          2. Patients who had participated in another investigational drug or device trial that has
             not completed the primary endpoint;

          3. Patients are, in the opinion of the investigator, unable to comply with the
             requirements of the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Tao, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital，Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Liu, MD, PhD</last_name>
    <phone>18602973275</phone>
    <email>1391643423@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruining Zhang, MS</last_name>
    <phone>86-029-84775183</phone>
    <email>liuyimeishan@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ling Tao</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Yuan F, Chen X, Song X, Wang D, Zhang Z, Li W, Li Z, Li H, Chen X, Huo Y, Wang L, Lu C, Lu Q, Xu B, Li W, Lyu S; HOPE Investigator. Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial. Chin Med J (Engl). 2014;127(14):2561-6.</citation>
    <PMID>25043067</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

